Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence

Chapter 1 From Newton to Nano: Beyond the Boundaries of the Possible Chapter 2 Healthcare’s Current Landscape, the Future, and Mars  Chapter 3 What is Nanomedicine? Chapter 4 Nanotechnology: A Perspective from Quantum Biology Chapter 5 Development of Universal Medical Millirobots Chapter 6 Shifting Paradigms in Healthcare Infrastructures Chapter 7 Technophysics, Smart Health Networks, and the Bio-Cryptoeconomy: Quantized Fungible Global Health Care Equivalency Units for Health and Well-Being Chapter 8 Synergies Between Nanotechnology and AI itowards GHCE Chapter 9 Ethical Implications of Global Health Care Equivalency Chapter 10 Beyond Diagnoses: Exploring Health through Systems, Behaviour, and Equity Chapter 11 Ethics, Nanotechnology, and Radical Life Extension Chapter 12 Introspective - AI/Human Interactions and Emergence of the Singularity: Ethical and Philosophical Implications Chapter 13 The Future Body: Nano Bodybuilders of Tomorrow

Biography

Frank J. Boehm has worked as a nanotechnology consultant, technology scout, product designer, research associate, and academic writer/editor for international corporations and university laboratories. Self-taught in nanotechnology and nanomedicine, Frank has developed numerous concepts for advanced nanomedical diagnostic and therapeutic systems. In 2009, he founded NanoApps Medical, Inc. to develop innovative and cost-effective nanomedical solutions for global benefit, and later co-founded NanoApps Athletics, Inc. in 2019. His published works include his first book on nanomedical device design (2013), multiple book chapters, journal articles, and an in-depth paper on "Human Brain/Cloud Interface." Currently, Frank is focused on a three-book series exploring the convergence of nanotechnology, nanomedicine, AI, and quantum computing to achieve global healthcare equivalency.

Raj Bawa is president of Bawa Biotech LLC, a biotech/pharma consultancy and patent law firm founded in 2002. Trained as a microbiologist and biochemist, he serves as a registered patent agent, scientific advisor to Teva Pharmaceutical Industries (since 2010), professor at Northern Virginia Community College (since 2004), and vice president/chief IP officer at Guanine, Inc. (since 2016). Dr. Bawa previously worked at the US Patent & Trademark Office (1990s-2002) as a primary examiner. He has led various research initiatives, including a CDC grant to develop an assay for carbapenemase-resistant bacteria. His education includes degrees in microbiology (BSc), cancer biology (MS), biophysics/biochemistry (PhD), and medicine (MD). Currently, he co-chairs nanotech and precision medicine committees for the American Bar Association and serves as founding director of the American Society for Nanomedicine. His contributions include over 100 publications, 10 edited texts, and editorial board service for numerous journals. His achievements have been recognized with awards including the Innovations Prize (2008), Appreciation Award from the Undersecretary of Commerce (2001), and Lifetime Achievement Award from the American Society for Nanomedicine (2014).